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Abstract 
Background: Although patients with advanced or metastatic lung cancer have poor prognosis, admission to the ICU 
for management of life‑threatening complications has increased over the years. Patients with newly diagnosed lung 
cancer appear as good candidates for ICU admission, but more robust information to assist decisions is lacking. The 
aim of our study was to evaluate the prognosis of newly diagnosed unresectable lung cancer patients.
Methods: A retrospective multicentric study analyzed the outcome of patients admitted to the ICU with a newly 
diagnosed lung cancer (diagnosis within the month) between 2010 and 2013.
Results: Out of the 100 patients, 30 had small cell lung cancer (SCLC) and 70 had non‑small cell lung cancer. (Thirty 
patients had already been treated with oncologic treatments.) Mechanical ventilation (MV) was performed for 81 
patients. Seventeen patients received emergency chemotherapy during their ICU stay. ICU, hospital, 3‑ and 6‑month 
mortality were, respectively, 47, 60, 67 and 71%. Hospital mortality was 60% when invasive MV was used alone, 71% 
when MV and vasopressors were needed and 83% when MV, vasopressors and hemodialysis were required. In multi‑
variate analysis, hospital mortality was associated with metastatic disease (OR 4.22 [1.4–12.4]; p = 0.008), need for inva‑
sive MV (OR 4.20 [1.11–16.2]; p = 0.030), while chemotherapy in ICU was associated with survival (OR 0.23, [0.07–0.81]; 
p = 0.020).
Conclusion: This study shows that ICU management can be appropriate for selected newly diagnosed patients 
with advanced lung cancer, and chemotherapy might improve outcome for patients with SCLC admitted for cancer‑
related complications. Nevertheless, tumors’ characteristics, numbers and types of organ dysfunction should be taken 
into account in the decisional process before admitting these patients in ICU.
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Background
Lung cancer is the most frequent malignancy world-
wide with an incidence of 1.8 million new cases a year 
in 2012 and the most common cause of death from can-
cer [1]. The development of targeted therapies and the 
emergence of immunotherapy [2, 3] recently improved 
outcome for patients with advanced and metastatic non-
small cell lung cancer. However, those patients remain 
exposed to numerous complications related to cancer 
itself, to treatments and to other comorbidities, and in 
many cases, require admission to intensive care units 
(ICUs) for their management.
ICU admission for cancer patients has been considered 
futile for a long time due to high mortality rates [4]. Lung 
cancer patients were particularly judged as poor can-
didates for ICU admission because their prognosis was 
thought to be even worse than other cancer patients [5]. 
However, improvement of the prognosis in ICU has been 
reported for patients with solid tumors over the last dec-
ades [6]. Taccone et al. [7] found that the mortality rate 
of cancer patients was similar as the general population. 
Other studies showed that cancer patients had mortality 
rates equivalent to patients with severe comorbidities like 
cardiac failure or cirrhosis [8, 9].
The main factors associated with mortality, such as 
acute respiratory failure [10–13], sepsis [10, 14, 15], more 
than two organ dysfunctions [12, 14, 15], the need for 
mechanical ventilation (MV) [10, 14–17], the need for 
vasopressors [15, 17, 18], a performance status ≥ 2 [11, 
13, 18] and metastatic [17] or progressive disease [12] 
have been assessed for all lung cancer patients. However, 
for patients with newly diagnosed lung cancer, factors 
associated with outcome have not yet been described.
The aim of our study was to evaluate the prognosis in 
ICU, at hospital, at 3 and 6 months of newly diagnosed 
unresectable lung cancer patients.
Patients and methods
Design of the study
This retrospective observational cohort study analyzed 
the medical records of lung cancer patients who were 
admitted to the ICU between January 2010 and Decem-
ber 2013, using two databases from twenty-one Euro-
pean and South American ICU. All centers are listed in 
“Appendix.” These two databases were the Lung Cancer in 
Critical Care (LUCCA) [19] database and the Saint-Louis 
Hospital’s database for patients admitted to ICU. For 
patients from LUCCA database, the study was initially 
approved by the Brazilian National Ethics Committee 
(approval number CONEP 15.790) and subsequently by 
local and national ethics committees in the participating 
centers and countries. For patients from Saint-Louis Hos-
pital, the ICU database was approved by the institutional 
review board (CECIC Clermont-Ferrand-IRB n5891; Ref: 
2007-16), which waived the need for signed informed 
consent of the participants, in accordance with French 
legislation on noninterventional studies.
Inclusion criteria, data collection
All patients aged over 18 years with a diagnosis of lung 
cancer admitted during the first month of diagnosis to 
the participating center’s ICUs could be included. Inclu-
sion criteria included a histologically proven lung can-
cer staged as locally advanced or metastatic. Patients 
admitted for postoperative care were excluded from the 
analysis.
The following variables were collected at admission: 
age, gender, medical background, time since diagno-
sis, main admission reason. Oncologic characterization 
was also collected and included the histological type, 
the extension of the disease (metastatic versus non-
metastatic), the potential preview anticancer treatments 
(chemotherapy, radiotherapy) and the pre-ICU (within 
the weeks before hospital admission) Eastern Coopera-
tive Oncology Group performance status (ECOG-PS) 
[20].
The severity of the illness was evaluated using the 
Sequential Organ Failure Assessment (SOFA) score [21] 
and the Simplified Acute Physiology Score II (SAPS II) 
[22] at admission. Comorbidities were determined with 
the Charlson Comorbidity Index (CCI) [23].
ICU’s interventions were defined by the use of MV, 
including noninvasive ventilation (NIV) and invasive 
mechanical ventilation (iMV), the use of vasopressors, 
hemodialysis and oncologic treatments. The decisions 
to withdrawal/withhold life-sustaining therapies (WLTs) 
were also collected.
The primary outcome was hospital mortality. Second-
ary outcomes were ICU mortality, 3- and 6-month mor-
tality. Also, patients who received chemotherapy during 
ICU stay were described.
Statistical analysis
All data are presented as frequencies (percentage) for 
qualitative variables and medians (25th–75th percentiles) 
for quantitative variables. The variable of interest for out-
come was hospital mortality. First, a univariate analysis 
was performed to compare patients who survived and 
patients who died during hospital stay, using nonpara-
metric Wilcoxon test or Chi-square test, as appropriate. 
A logistic regression analysis was performed to identify 
independent prognostic variables among six character-
istics of patients during ICU stay and ICU interventions 
(metastatic disease, chemotherapy during ICU, need and 
mode of mechanical ventilation, need of vasopressor). 
Two-sided p values < 0.050 were considered significant. 
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The subgroup of patients who received chemotherapy 
during ICU stay was described. No comparisons were 
made in this subgroup of interest. Survival curves at 
6 months were plotted using the Kaplan–Meier method. 
All statistical analyses were performed with Statview 
(SAS Institute Inc, USA).
Results
Patients’ characteristics
From January 2010 through December 2013, 100 patients 
admitted in ICU met the inclusion criteria (Fig.  1). 
Patients’ characteristics are summarized in Table 1.
The median time between cancer diagnosis and ICU 
admission was 7 days [0–20.0 days]; 31 patients had their 
diagnosis confirmed during their ICU stay.
Seventy-five percent of the patients had a good perfor-
mance status (ECOG-PS = 0–1) before ICU admission. 
At admission, medians of SOFA, SAPS II and CCI scores 
were, respectively, of 8 [4.0–12.0], 52 [41.0–64.0] and 3 
[3–6].
The main reasons for admission in ICU were acute res-
piratory failure (except from septic cause) (n = 46), septic 
shock (n = 40), cardiogenic shock (n = 4), coma (n = 4), 
cardiac arrest (n = 2) and miscellaneous reasons (n = 4). 
Among these admission reasons, 74% of patients pre-
sented with one or more lung cancer-related complica-
tion (37 with airway obstruction, 27 with pleural infusion, 
13 with superior vena cava syndrome, 8 with pericardial 
effusion, 4 with spinal cord compression, 2 with intracra-
nial hypertension and 17 with other complications). For 
Patients included in LUCCA
study
N=449
Patients admitted to ICU in
LUCCA study 2010-2011
N=20351
Patients admitted to Saint
Louis ICU 2012-2013
N=1631
Patients with lung cancer
N=82
Patients with lung cancer
diagnosed within the month
before ICU admission
N=90
Patients with lung cancer
diagnosed within the month
before ICU admission
N=10
Patients included in the study
N=100
Patients without lung cancer
N=19902
Patients without lung cancer
N=1549
Patients with lung cancer for
more than one month
N=359
Patients with lung cancer for
more than one month
N=72
Fig. 1 Flowchart
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some patients, cancer-related complications led to the 
diagnostic of cancer.
ICU interventions
The median length of ICU stay was 8 days [3.0–15.0], and 
median length of hospital stay was 22 days [12.0–32.0].
Eighty-one patients required mechanical ventilation 
during 6 days [3.0–15.0]. Among these patients, 44 (54%) 
received iMV at first line, 21 (26%) were initially venti-
lated with NIV and subsequently required intubation for 
iMV, and 16 (20%) were only ventilated with NIV. Vaso-
pressors were needed for 61 patients and renal replace-
ment therapies for 12 patients.
Outcome analysis
Hospital mortality was 60%. ICU, 3 and 6-month mor-
tality rates were, respectively, 47, 67 and 71%. For 
50 patients, withdrawal/withhold of life-sustaining 
therapies (WLTs) were decided after 6  days [2.0–14.5]. 
Among these patients, 36 patients died in ICU and nine 
patients died after ICU discharge. Mortality was not dif-
ferent according to the reason of ICU admission (sep-
sis versus acute respiratory failure, p = 0.32) (data not 
shown).
Mortality of patients differed according to the number 
of organ failures: hospital mortality was 60% (n = 6/10) 
when patient required only mechanical ventilation, 71% 
(n = 35/49) when patients required mechanical ventila-
tion and vasopressors, and 83% (n = 10/12) when they 
had multiple organ failures. The histological type of can-
cer was not associated with 6-month mortality (Fig. 2).
Tables 2 and 3 describe patients’ characteristics accord-
ing to hospital mortality. Metastatic disease (78 vs 57.5%, 
p = 0.040), SOFA score (8 [6.0–14.5] vs 5 [3.5–9.5], 
p = 0.010), SAPS II score (56.5 [46.5–71.0] vs 42.5 [36.5–
55.5], p = 0.002), need for MV (90 vs 67.5%, p = 0.005), 
need for vasopressors (75 vs 40%, p < 0.001) and WLT 
decisions (75 vs 12.5%, p < 0.001) were associated with 
higher mortality. The use of emergency chemotherapy in 
ICU, although not statistically significant, showed a trend 
toward better survival (25 vs 12%, p = 0.080).
Factors independently associated with hospital mor-
tality are reported in Table 4.
Cancer treatment
Twenty patients received chemotherapy as front-line 
treatment of their cancer; 10 were treated with radiother-
apy. (Six among these ten received combined regimens of 
radiotherapy and chemotherapy.) The details of oncologic 
treatments were not available in the databases.
Seventeen patients received chemotherapy during 
ICU stay, mostly presenting with SCLC.
In total, most of the patients did not receive cancer 
treatment before ICU discharge and chemotherapy could 
eventually be decided after ICU stay.
Table 1 Patients’ characteristics at ICU admission
IQR interquartile range, COPD chronic obstructive pulmonary disease, DVT deep 
vein thrombosis, SCLC small cell lung cancer, ECOG-PS Eastern Cooperative 
Oncology Group performance status, SOFA Sequential Organ Failure 
Assessment, SAPS II Simplified Acute Physiology Score, version II, CCI Charlson 
Comorbidity Index
Characteristics n (total = 100)
Age, in years median [IQR] 64 [56.0–72.0]
Male gender 68
Comorbidities
 COPD 13
 Hypertension 43
 Diabetes 18
 Cirrhosis 2
 Angina 5
 Arrhythmia 13
 DVT 5
 Stroke 5
 Malnourishment 11
Days since diagnosis, median [IQR] 7 [0–20.0]
Histological type
 SCLC 30
 Adenocarcinoma 28
 Squamous cell carcinoma 25
 Large cell carcinoma 5
 Other 12
Metastatic disease 70
ECOG‑PS
 Low (0–1) 75
 High (≥ 2) 24
 Unknown 1
SOFA score, points, median [IQR] 8 [4.0–12.0]
SAPS II, points, median [IQR] 52 [41.0–64.0]
CCI, points, median [IQR] 0.5 [0–3.0]
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p=0.39
Fig. 2 Kaplan–Meier survival curve according to the cancer histology
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Outcome of patients who received emergency 
chemotherapy in ICU
Seventeen patients received emergency chemother-
apy while in ICU. Mostly they had small cell lung can-
cer (SCLC) (n = 11), performance status was good 
(ECOG-PS < 2 for 14 patients) and they had few comor-
bidities (CCI of 0 [0–2.0]). SOFA and SAPSII scores 
were, respectively, of 7 [3.0–8.0] and 51 [39.0–59.0]. 
None of these patients had received previous oncologic 
treatment for lung cancer. Except one, they all required 
MV during ICU stay. For 15 patients (88%), the reason 
for emergency chemotherapy was cancer-related severe 
acute complications. The most frequent complications 
were airway obstruction related to cancer (n = 10/15, 
67%) and/or pleural effusion (n = 5/15, 33%). ICU, 
Table 2 Univariate analysis of risk factors associated with hospital mortality
IQR interquartile range, SCLC small cell lung cancer, NSCLC non-small cell lung cancer, SOFA Sequential Organ Failure Assessment, SAPS II Simplified Acute Physiology 
Score, version II, ECOG-PS Eastern Cooperative Oncology Group performance status, CPA cardiopulmonary arrest
Variables Survival patients n = 40 (40%) Dead patients n = 60 (60%) p value
Age in years, median [IQR] 63 [52.0–71.0] 65.5 [57.0–73.0] p = 0.250
Males, n (%) 29 (72.5) 39 (65) p = 0.560
Days since diagnosis, median [IQR] 4 [0–20.5] 7.5 [0–20.5] p = 0.460
Histological type, n (%) p = 0.790
 SCLC 12 (30) 18 (30)
 NSCLC 28 (70) 42 (70)
Metastatic disease, n (%) 23 (57.5) 47 (78) p = 0.040
Prior chemotherapy, n (%) 7 (17.5) 13 (22) p = 0.170
Prior radiotherapy, n (%) 3 (7.5) 7 (12) p = 0.250
ECOG‑PS, n (%) p = 0.920
 Low (0–1) 31 (78) 44 (73)
 High 9 (22.5) 15 (25)
SOFA score, points, median [IQR] 5 [3.5–9.5] 8 [6.0–14.5] p = 0.010
SAPS II, points, median [IQR] 42.5 [36.5–55.5] 56.5 [46.5–71.0] p = 0.002
Admission reason, n (%) p = 0.330
 Sepsis 12 (30) 28 (47)
 Respiratory (excluding septic reasons) 21 (52.5) 25 (42)
 Cardiovascular disease 2 (5) 2 (3)
 Neurologic 2 (5) 2 (3)
 Post‑CPA 0 2 (3)
 Other 3 (7.5) 1 (2)
Table 3 Univariate analysis of ICU’s interventions associated 
with hospital mortality
ICU intensive care unit, MV mechanical ventilation, iMV invasive mechanical 
ventilation, NIV noninvasive ventilation, WLTs withdrawal/withhold life-
sustaining therapies
Variable Survival 
patients n = 40 
(40%)
Dead 
patients 
n = 60 (60%)
p value
Mechanical ventilation, 
n (%)
p = 0.005
 No MV 13 (32.5) 6 (10)
 NIV alone 9 (22.5) 7 (12)
 iMV at first line 11 (27.5) 33 (55)
 iMV after NIV 7 (17.5) 14 (23)
Catecholamines, n (%) 16 (40) 45 (75) p < 0.001
Hemodialysis, n (%) 2 (5) 10 (17) p = 0.060
Oncologic treatment in 
ICU, n (%)
p = 0.080
 Chemotherapy 10 (25) 7 (12)
WLT 5 (12.5) 45 (75) p < 0.001
Table 4 Multivariate analysis of risk factors independently 
associated with hospital mortality
OR odds ratio, CI confidence interval, iMV invasive mechanical ventilation, NIV 
noninvasive ventilation
Variable OR [95%CI] p value
Metastatic disease 4.22 [1.4–12.4] p = 0.008
Chemotherapy in ICU 0.23 [0.07–0.81] p = 0.020
Vasopressor 2.67 [0.8–8.9] p = 0.100
Mechanical ventilation
 NIV alone or no mechanical 
ventilation
1
 iMV after NIV 4.18 [0.88–19.9] p = 0.070
 iMV at first line 4.2 [1.11–16.2] p = 0.030
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hospital, 3- and 6-month mortality rate were, respec-
tively, 29, 41, 53 and 59%. Among the ten patients dis-
charged from hospital (including eight with SCLC), eight 
patients (80%) were alive at 3  months (all SCLC) and 
seven patients (70%) were alive at 6  months. For those 
patients who received MV and vasopressors, mortality 
rate was 46% and for those with multiple organ failure 
mortality rates was 50%.
Discussion
In this multicentric, retrospective study, patients with 
newly diagnosed lung cancer admitted to ICU had 
acceptable ICU and hospital mortality rates of, respec-
tively, 47 and 60%. However, mortality rates at three 
and 6  months remained substantially high (respectively, 
67 and 71%). As expected, mortality rates rose with the 
severity of acute illness. Although mortality for patients 
who required only iMV was 60%, it reached 83% for 
patients with multiple organ failure. Those results were 
consistent with previous studies [12, 14, 15, 24] and could 
raise questions about the futility of intensive care for 
these last patients. In our study, decision to withhold or 
withdrawal life-sustaining therapies occurred for half of 
the patients with a high rate of mortality. (Seventy-two 
percentage of these patients died in ICU and 90% in the 
hospital.) Decreasing the number of unnecessary aggres-
sive care is a major concern in this population, espe-
cially with the increasing number of patients treated for 
advanced cancer and therefore the number of patients 
with cancer-related emergencies [25]. The decisional pro-
cess should include intensivists, oncologists and palliative 
care services. Triage criteria for this specific population 
of patients are still imperfect [9], and prognosis factors 
have been pursued to select patients who would benefit 
the most from intensive cares. Moreover, triage criteria 
should be frequently reassessed according to new treat-
ment, and survival improvement in that setting [26].
Various factors are associated with mortality in the 
studies [27]. Besides organ failure related to acute dis-
ease, we found in our study two factors independently 
associated with hospital outcome and related to cancer 
characteristics. Metastatic disease was associated with 
mortality (p = 0.003), and the administration of chemo-
therapy during ICU stay was associated with survival 
(p = 0.020). In contrast to other previous studies [11, 13, 
18], performance status was not associated with hospital 
mortality. This result could be related to the proportion 
of patients with good performance status in our cohort 
and to the analysis of hospital mortality only and not 
long-term outcome. Moreover, other prognosis factors 
have been described in oncology for advanced cancer 
patients, such as anorexia–cachexia syndrome, delir-
ium, leukocytosis, lymphocytopenia, levels of C-reactive 
protein [28] or combinations of criteria, including Kar-
nofsky index, number of metastatic sites, levels of serum 
albumin and lactate dehydrogenase (LDH) concentration 
[29]. They should be assessed for critically ill patients 
with inaugural diagnosis. Prospective large multicentric 
studies or meta-analysis is needed.
Our study added interesting data about critically ill 
lung cancer patients at the diagnosis of their malignancy. 
Studies concerning newly diagnosed lung cancer patients 
with life-threatening complications remained scarce [30, 
31]. We defined new diagnosis as diagnosis within the 
month of ICU admission so that patients would not have 
received more than one line of treatment. Our results 
appear similar to recent studies on critically ill lung can-
cer patients, at different times of their disease [12, 18, 19].
A major strength of our study was that 17 patients 
were able to receive chemotherapy during their ICU 
stay. These patients presented mostly with SCLC. 
Chemotherapy was prescribed during ICU stay for 
88% of patients because of cancer-related complica-
tions. Among these patients, ICU, hospital, 3- and 
6-month mortality rates were, respectively, 29, 41, 53 
and 59%. Receiving chemotherapy in ICU was inde-
pendently associated with survival (p = 0.020). This 
suggested that rescue chemotherapy in ICU is feasi-
ble in selected patients and had a positive outcome. It 
also suggests that the tumor’s chemo-sensitivity is an 
important factor that should be taken into account in 
the decision of admitting patients in ICU. Because of 
their high response rate to chemotherapy [32], patients 
with SCLC remained good candidates for ICU admis-
sion at diagnosis. These results are consistent the study 
of Zerbib et  al. [33] in which SCLC has been identi-
fied as an independent predictor of hospital survival 
for patients receiving chemotherapy in ICU for organ 
failure related to solid neoplasms. In another study by 
Chen et al. [30], ICU and hospital survival were better 
for patients who received either chemotherapy or epi-
dermal growth factor receptor-tyrosine kinase inhibi-
tor (EGFR-TKI) therapy compared with those receiving 
best supportive care. They also found that ICU survival 
was independently associated with the use of mechani-
cal ventilation, which is different from our results. This 
difference might be explained by the particular popula-
tion of the study composed by a high number of patient 
treated with EGFR-TKI with usually high rate of good 
and quick response to treatment [34]. Newly diagnosed 
lung cancer patients, especially those with high sensi-
tivity to anticancer treatment admitted to the ICU for 
cancer-related complications, appear as a specific sub-
group of patient who might benefit from invasive cares. 
Other studies are warranted to confirm those results, to 
explore the type and timing of anticancer therapy for 
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this subpopulation, and data must be considered with 
caution over time since therapeutic advances in oncol-
ogy are substantial. However, the increasing number of 
treated patients would lead to high rate of critical care 
admission. The decision for ICU admission, but also the 
assessment of the goals of care during ICU stay, should 
include intensivist, oncologist and palliative care phy-
sician to improve the best care for those patients [9]. 
Studies are needed to improve the best model of deliv-
ering care in that setting.
The present study has several limitations. First, it 
was retrospective, monocentric and focused on a small 
number of patients admitted to ICU. Although all 
the patients were diagnosed with lung cancer within 
1  month and had a good performance status before 
ICU admission, the possibility of cancer treatment after 
complications leading to ICU admission could be small 
[35]. There were no details concerning triage decisions, 
and we could not analyze the outcome of patients who 
were referred, but not admitted, to the ICU. Second, 
the choice of the severity scores that has been made in 
this study can be debated. We use the SOFA and the 
SAPSII scores, but no differences have been clearly 
found between the different existing scores [36, 37] 
and others such as the Acute Physiology and Chronic 
Health Evaluation (APACHE) could have been used 
[38] in the specific population of cancer patients. Third, 
only a small number of patients received chemother-
apy. There was a lack of details regarding the oncologic 
treatments received before ICU admission and type of 
chemotherapy regimens used during ICU stay, which 
might have an impact on the outcome. Tolerance and 
treatment-related toxicities of chemotherapy have not 
been recorded and were other important issues. Other 
treatments for non-small cell lung cancer (NSCLC), 
such as targeted therapies, were not analyzed in this 
study. However, some studies [30] confirmed improve-
ments in the outcome for specific patients admitted to 
ICU with mutated NSCLC. Fourth, we did not describe 
outcome according to the metastatic stage. However, 
for ICU patients, number of metastatic site was not 
related to outcome in recent study [30]. Also, for some 
patients with diagnosis performed during ICU, meta-
static stage was not completely known at ICU admis-
sion. Lastly, although 40% of patients were still alive 
at hospital discharge, we do not have any information 
about the quality of life and the possibilities to receive 
further oncologic treatments.
In conclusion, this multinational study showed that 
ICU management was appropriate for newly diagnosed, 
unresectable lung cancer patients. Nevertheless, tumor’s 
characteristics, number of organ dysfunctions and types 
of intensive interventions should be taken into account 
before admitting these patients in ICU. Metastatic dis-
ease and need for immediate invasive iMV were associ-
ated with mortality, and mortality rose with the severity 
of acute illness. The tumor’s chemo-sensitivity should 
also be estimated since rescue chemotherapy in ICU 
was associated with survival and should be proposed for 
selected patients, especially for those with cancer-related 
complications.
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Appendix
Participating centers for the LUCCA database
Argentina
Instituto Medico Especializado Alexander Fleming, Bue-
nos Aires (Célica Irrazábal, Pierina Bachetti).
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Brazil
Instituto Nacional de Câncer, Rio de Janeiro (Vicente C. 
Souza-Dantas, Mauro M. Zamboni, Aureliano Sousa).
Hospital A. C. Camargo, São Paulo (Bruno F. C. 
Almeida, Lúcio S. Santos, Pedro Caruso), Fundação Pio 
XII - Hospital de Câncer de Barretos, Barretos (Ulysses 
V. A. Silva).
Hospital Sírio Libanês, São Paulo (Luciano C. P. 
Azevedo, Guilherme P. P. Schettino).
Vitória Apart Hospital, Vitória (Cláudio Piras, Stéph-
anie B. Piras, Albano S. M. T. Silva).
Chile
Hospital Clinico Universidad de Chile, Santiago (Eduado 
Tobar, Nivia Estuardo).
France
Institut Gustave Roussy, Villejuif (François Blot, Bruno 
Raynard).
Hôpital Tenon, Paris (Antoine Parrot).
Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, 
Lyon (Florent Wallet).
Institut Mutualiste Montsouris, Paris (Christian 
Lamer).
Groupe Hospitalier Pitié Salpêtrière, Paris (Alexandre 
Duguet, Alexandre Demoule, Julie Delemazure, Julien 
Mayaux, Thomas Similowski).
Hôpital A. Michallon, CHU de Grenoble, Grenoble 
(Surgical ICU: Michel Durand, Geraldine Dessertaine, Pr 
Jean François Payen; Medical ICU: Anne-Claire Toffart, 
Jean-François Timsit).
Hôpital de la Croix-Rousse, Lyon (Gael Bourdin, 
Claude Guerin).
Hôpital Hôtel Dieu de Paris, Paris (Antoine Rabbat; 
Aurélie Lefebvre).
Hôpital Saint-Louis, Paris (Élie Azoulay).
United Kingdom
Royal Marsden Hospital, London (Natalie Pattison).
Royal Brompton NHS Foundation Trust, London 
(Natalie Pattison).
Uruguay
Hospital Maciel, Montevideo (Gastón Burghi).
Asocianción Española Primera de Socorros Mutuos, 
Montevideo (Gastón Burghi).
Hospital de Clínicas, Montevideo (Gastón Burghi).
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